Your browser doesn't support javascript.
loading
ALSUntangled #67: rituximab.
Li, Xiaoyan; Armon, Carmel; Barkhaus, Paul; Barnes, Benjamin; Benatar, Michael; Bertorini, Tulio; Bromberg, Mark; Carter, Gregory T; Crayle, Jesse; Cudkowicz, Merit; Dimachkie, Mazen; Feldman, Eva L; Glass, Jonathan; Goslinga, Jill; Heiman-Patterson, Terry; Jhooty, Sartaj; Lichtenstein, Rachel; Lund, Isaac; Mcdermott, Christopher; Pattee, Gary; Pierce, Kaitlyn; Ratner, Dylan; Salmon, Kristiana; Wicks, Paul; Bedlack, Richard.
Afiliación
  • Li X; Department of Neurology, Duke University, Durham, NC, USA.
  • Armon C; Department of Neurology, Loma Linda University, Loma Linda, CA, USA.
  • Barkhaus P; Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Barnes B; Department of Neurology, Medical College of Georgia, Augusta, GA, USA.
  • Benatar M; Department of Neurology, University of Miami, Miami, FL, USA.
  • Bertorini T; Neurology Department, University of Tennessee Health Science Center, Memphis, TN, USA.
  • Bromberg M; Department of Neurology, University of Utah, Salt Lake City, UT, USA.
  • Carter GT; Department of Rehabilitation, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.
  • Crayle J; Neurology Department, Washington University, St. Louis, MO, USA.
  • Cudkowicz M; Department of Neurology, Harvard Medical School, Boston, MA, USA.
  • Dimachkie M; Department of Neurology, University of Kansas, Kansas City, KS, USA.
  • Feldman EL; Department of Neurology, University of Michigan, Ann Arbor, MI, USA.
  • Glass J; Department of Neurology, Emory University, Atlanta, GA, USA.
  • Goslinga J; Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
  • Heiman-Patterson T; Department of Neurology, Temple Health, Philadelphia, PA, USA.
  • Jhooty S; University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Lichtenstein R; Avram and Stella Goren-Goldstein Biotechnology Engineering Department, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Lund I; Undergraduate, Green Hope High School, Cary, NC, USA.
  • Mcdermott C; Department of Neuroscience, University of Sheffield, Sheffield, UK.
  • Pattee G; Department of Neurology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Pierce K; Department of Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Ratner D; Undergraduate, Longmeadow High School, Longmeadow, MA, USA.
  • Salmon K; Department of Neurology, Montreal Neurological Institute, Montreal, CA and.
  • Wicks P; Independent Consultant, Lichfield, UK.
  • Bedlack R; Department of Neurology, Duke University, Durham, NC, USA.
Amyotroph Lateral Scler Frontotemporal Degener ; 24(5-6): 544-547, 2023 08.
Article en En | MEDLINE | ID: mdl-36106861
ABSTRACT
ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS who ask about them. Here we review rituximab, a drug which specifically depletes B lymphocytes. We show a current lack of evidence for a role of these cells in ALS progression. The one patient we found who described using Rituximab for their ALS found no benefit. Given all this, and the known serious risks of rituximab, we advise against its use as an ALS treatment.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Rituximab / Esclerosis Amiotrófica Lateral Límite: Humans Idioma: En Revista: Amyotroph Lateral Scler Frontotemporal Degener Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Rituximab / Esclerosis Amiotrófica Lateral Límite: Humans Idioma: En Revista: Amyotroph Lateral Scler Frontotemporal Degener Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos